FDA NEWS RELEASE
For Immediate Release: July 23, 2013
Media Inquiries: Jennifer Haliski, 301-796-0776, email@example.com
Consumer Inquiries: 888-INFO-FDA
FDA invites public input on menthol in cigarettes
Today, the U.S. Food and Drug Administration issued an Advance Notice of Proposed Rulemaking
(ANPRM) seeking additional information to help the agency make informed decisions about menthol in cigarettes.
Despite decades of work to reduce tobacco use in the United States, it continues to be the leading cause of preventable death and disease. In the United States, about 30 percent of all adult smokers and more than 40 percent of all youth smokers report smoking menthol cigarettes.
“Menthol cigarettes raise critical public health questions,” said FDA Commissioner Margaret A. Hamburg, M.D. “The FDA is committed to a science-based approach that addresses the public health issues raised by menthol cigarettes, and public input will help us make more informed decisions about how best to tackle this important issue moving forward.”
The agency is issuing the ANPRM to obtain additional information related to potential regulatory options it might consider, such as establishing tobacco product standards, among others.
The ANPRM will be available for public comment for 60 days. The FDA will consider all comments, data, research, and other information submitted to the docket to determine what, if any, regulatory action with respect to menthol in cigarettes is appropriate. If the FDA decides to issue a rule, the first step in that process would be a Notice of Proposed Rulemaking, which would give the public an opportunity to weigh in on the specifics of the proposed rule.
“FDA’s actions today on menthol reflect our commitment to explore all potential options, including the establishment of product standards. In the meantime, we will conduct new research to further inform our decision making,” said Mitch Zeller, J.D., director of the FDA’s Center for Tobacco Products.
In addition, the FDA plans to support new research on the differences between menthol and nonmenthol cigarettes as they relate to menthol’s likely impact on smoking cessation and attempts to quit, as well as assessing the levels of menthol in cigarette brands and sub-brands. The FDA is funding three menthol-related studies; one to look at whether genetic differences in taste perceptions explain why certain racial and ethnic populations are more likely to use menthol cigarettes; the second to compare exposure to smoke-related toxins and carcinogens from menthol and nonmenthol cigarettes; and a third to examine the effects of menthol and nonmenthol compounds in various tobacco products on both tobacco addiction and toxicants of tobacco smoke.
Finally, the FDA is developing a youth education campaign focused on preventing and reducing tobacco use, including menthol cigarettes.
For more information:
The FDA, an agency within the U.S. Department of Health and Human Services, protects the public health by assuring the safety, effectiveness, and security of human and veterinary drugs, vaccines and other biological products for human use, and medical devices. The agency also is responsible for the safety and security of our nation’s food supply, cosmetics, dietary supplements, products that give off electronic radiation, and for regulating tobacco products.
Read our Blog: FDA Voice
Visit the FDA on Facebook, Flickr , YouTube , and Twitter
RSS Feed for FDA News Releases